228 related articles for article (PubMed ID: 19494338)
1. Reduced expression of the mevalonate pathway enzyme farnesyl pyrophosphate synthase unveils recognition of tumor cells by Vgamma9Vdelta2 T cells.
Li J; Herold MJ; Kimmel B; Müller I; Rincon-Orozco B; Kunzmann V; Herrmann T
J Immunol; 2009 Jun; 182(12):8118-24. PubMed ID: 19494338
[TBL] [Abstract][Full Text] [Related]
2. DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vgamma9Vdelta2 T cells.
Toutirais O; Cabillic F; Le Friec G; Salot S; Loyer P; Le Gallo M; Desille M; de La Pintière CT; Daniel P; Bouet F; Catros V
Eur J Immunol; 2009 May; 39(5):1361-8. PubMed ID: 19404979
[TBL] [Abstract][Full Text] [Related]
3. In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vγ9Vδ2 T-cell antitumor cytotoxicity through ICAM-1 engagement.
Benzaïd I; Mönkkönen H; Bonnelye E; Mönkkönen J; Clézardin P
Clin Cancer Res; 2012 Nov; 18(22):6249-59. PubMed ID: 23032740
[TBL] [Abstract][Full Text] [Related]
4. F1-adenosine triphosphatase displays properties characteristic of an antigen presentation molecule for Vgamma9Vdelta2 T cells.
Mookerjee-Basu J; Vantourout P; Martinez LO; Perret B; Collet X; Périgaud C; Peyrottes S; Champagne E
J Immunol; 2010 Jun; 184(12):6920-8. PubMed ID: 20483757
[TBL] [Abstract][Full Text] [Related]
5. Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients.
Viey E; Lucas C; Romagne F; Escudier B; Chouaib S; Caignard A
J Immunother; 2008 Apr; 31(3):313-23. PubMed ID: 18317356
[TBL] [Abstract][Full Text] [Related]
6. Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates.
Sanders JM; Ghosh S; Chan JM; Meints G; Wang H; Raker AM; Song Y; Colantino A; Burzynska A; Kafarski P; Morita CT; Oldfield E
J Med Chem; 2004 Jan; 47(2):375-84. PubMed ID: 14711309
[TBL] [Abstract][Full Text] [Related]
7. Expansion of human peripheral blood γδ T cells using zoledronate.
Kondo M; Izumi T; Fujieda N; Kondo A; Morishita T; Matsushita H; Kakimi K
J Vis Exp; 2011 Sep; (55):. PubMed ID: 21931292
[TBL] [Abstract][Full Text] [Related]
8. Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro.
Thompson K; Rogers MJ
J Bone Miner Res; 2004 Feb; 19(2):278-88. PubMed ID: 14969398
[TBL] [Abstract][Full Text] [Related]
9. IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy.
Thedrez A; Harly C; Morice A; Salot S; Bonneville M; Scotet E
J Immunol; 2009 Mar; 182(6):3423-31. PubMed ID: 19265120
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of the mevalonate pathway by cholesterol depletion abolishes tolerance to N-bisphosphonate induced Vγ9Vδ2 T cell cytotoxicity in PC-3 prostate cancer cells.
Arkko S; Zlatev HP; Mönkkönen H; Räikkönen J; Benzaïd I; Clézardin P; Mönkkönen J; Määttä JA
Cancer Lett; 2015 Feb; 357(1):279-285. PubMed ID: 25444923
[TBL] [Abstract][Full Text] [Related]
11. Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells.
Räikkönen J; Mönkkönen H; Auriola S; Mönkkönen J
Biochem Pharmacol; 2010 Mar; 79(5):777-83. PubMed ID: 19819230
[TBL] [Abstract][Full Text] [Related]
12. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo.
Benzaïd I; Mönkkönen H; Stresing V; Bonnelye E; Green J; Mönkkönen J; Touraine JL; Clézardin P
Cancer Res; 2011 Jul; 71(13):4562-72. PubMed ID: 21646473
[TBL] [Abstract][Full Text] [Related]
13. A regulatory cross-talk between Vgamma9Vdelta2 T lymphocytes and mesenchymal stem cells.
Martinet L; Fleury-Cappellesso S; Gadelorge M; Dietrich G; Bourin P; Fournié JJ; Poupot R
Eur J Immunol; 2009 Mar; 39(3):752-62. PubMed ID: 19197941
[TBL] [Abstract][Full Text] [Related]
14. Innate immune functions of human gammadelta T cells.
Beetz S; Wesch D; Marischen L; Welte S; Oberg HH; Kabelitz D
Immunobiology; 2008; 213(3-4):173-82. PubMed ID: 18406365
[TBL] [Abstract][Full Text] [Related]
15. ABCA1, apoA-I, and BTN3A1: A Legitimate Ménage à Trois in Dendritic Cells.
Riganti C; Castella B; Massaia M
Front Immunol; 2018; 9():1246. PubMed ID: 29937767
[TBL] [Abstract][Full Text] [Related]
16. Correlation between time-dependent inhibition of human farnesyl pyrophosphate synthase and blockade of mevalonate pathway by nitrogen-containing bisphosphonates in cultured cells.
Räikkönen J; Taskinen M; Dunford JE; Mönkkönen H; Auriola S; Mönkkönen J
Biochem Biophys Res Commun; 2011 Apr; 407(4):663-7. PubMed ID: 21420384
[TBL] [Abstract][Full Text] [Related]
17. Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors.
Bonneville M; Scotet E
Curr Opin Immunol; 2006 Oct; 18(5):539-46. PubMed ID: 16870417
[TBL] [Abstract][Full Text] [Related]
18. Repeated systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells efficiently control tumor development in vivo.
Santolaria T; Robard M; Léger A; Catros V; Bonneville M; Scotet E
J Immunol; 2013 Aug; 191(4):1993-2000. PubMed ID: 23836057
[TBL] [Abstract][Full Text] [Related]
19. Human Vgamma9Vdelta2 T cells: from signals to functions.
Nedellec S; Bonneville M; Scotet E
Semin Immunol; 2010 Aug; 22(4):199-206. PubMed ID: 20447835
[TBL] [Abstract][Full Text] [Related]
20. CRTAM receptor engagement by Necl-2 on tumor cells triggers cell death of activated Vγ9Vδ2 T cells.
Dessarthe B; Thedrez A; Latouche JB; Cabillic F; Drouet A; Daniel P; de La Pintière CT; Catros V; Toutirais O
J Immunol; 2013 May; 190(9):4868-76. PubMed ID: 23530148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
